An interventional study of Audit-and-feedback in Anti-Bacterial Agents and Respiratory Tract Infections, sponsored by Iowa City Veterans Affairs Medical Center. Completed at 2 sites in United States. Per ClinicalTrials.gov, last updated 2021-04-28.
Sponsored by Iowa City Veterans Affairs Medical Center · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 210 studies in Respiratory Tract Infections with a site in United States — 20 open to participants now, 28 under way, 5 of them phase 3. Respiratory Tract Infections · United States.
Among the 210 studies in Respiratory Tract Infections with a site in United States, this one is the 140th largest by enrollment of the 160 interventional ones that give a count, is one of 10 that started in 2018, is one of 66 with no phase, and was the 112th registered.
753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.
Browse Respiratory Tract Infections studies →20 of the 210 studies in Respiratory Tract Infections with a site in United States are open now. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 7–17 · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
University Hospital, Grenoble · Sites in United States, France, Germany and 2 more countries
Ages 60+
Timothy Shope · Sites in United States
Ages 6 mo–24 mo
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
210 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 42 · Phase 3 22 · Phase 4 14
First in 1997; this study’s year is marked. 10 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.
Median enrollment 137 across the 160 interventional studies, 558 across the 48 observational. Of the 172 that completed or were terminated, 67 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
85 of 210 have an industry lead sponsor. The 10 most frequent:
Iowa City Veterans Affairs Medical Center is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Iowa City Veterans Affairs Medical Center has 1 study filed under Respiratory Tract Infections — fewer than ten, so there is no comparison to draw.
14 of the studies in Respiratory Tract Infections with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-12 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05474430Philip PolgreenEstimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity | 2026-12 |
Add all 14 to your calendar (.ics) → With an account.
Among the 210 studies in Respiratory Tract Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Antimicrobial resistance is one of today's most urgent public health problems. One of the most important strategies to slow the spread of antimicrobial resistance is the promotion of judicious antimicrobial use. There are tremendous opportunities to reduce unnecessary antimicrobial-prescribing, particularly in Emergency Departments (EDs). In this study, the investigators will work collaboratively with ED providers in the Veterans Health Administration (VHA) to reduce unnecessary antimicrobial use. Academic-detailing and an audit-and-feedback intervention will be implemented, and the study will assess how overall antimicrobial-prescribing changes once these interventions are performed. ED providers will be shown how their antimicrobial-prescribing compares to their peers, thereby encouraging them to consider their professional reputation when making prescribing decisions. To assess the impact of this intervention, the study will monitor providers' antimicrobial-prescribing behavior through an automated metric, i.e. number of antimicrobial prescriptions per number of patient-visits. To assess changes in the appropriateness of antimicrobial-prescribing, the study team will also perform manual chart reviews and compare prescribing decisions to published guidelines.
Using a quasi-experimental design, the study team will work collaboratively with ED providers in the Veterans Health Administration (VHA) to improve antimicrobial-prescribing. Academic-detailing and an audit-and-feedback intervention will be implemented. Through audit-and-feedback, providers will be shown how their antimicrobial-prescribing compares to their peers, thereby encouraging them to consider their professional reputation when making prescribing decisions.
The study will use a pretest-posttest design (quasi-experimental design with a non-equivalent control group) to assess the effect of our pilot intervention at 2 participating EDs and 2 control EDs. For each ED, the pretest period will be the 12 months prior to the intervention. The intervention itself will last 12 months.
There will be an estimated 30 ED providers at the 2 study sites and 30 ED providers at the 2 control sites. Only antimicrobial prescriptions to patients discharged from the ED will be evaluated.
The primary outcome will be antimicrobial-prescribing volume adjusted for the total number of patient-visits. Secondary outcomes include the frequency of guideline-discordant antimicrobial-prescribing and adverse events.
At the conclusion of the pilot trial, a quasi-experimental interrupted time-series (ITS) analysis will be performed to assess the change in monthly antimicrobial usage for the 2 intervention sites combined and the 2 control sites combined. The time frame for this ITS analysis will be the one-year prior to the pilot trial's initiation through the trial's 1-year intervention period for a total of 24 months. In addition, a multivariable analysis will be performed to identify predictors of guideline-discordant therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
--An ED provider at one of the intervention or control sites.
Exclusion Criteria:
--An ED provider who sees less than 100 patients in the ED per year.
The experimental arm will consist of Emergency Department providers who do receive the intervention.
Behavioral: Audit-and-feedback
The control arm will consist of providers who do not receive the intervention.
We will monitor the antimicrobial-prescribing of providers in the experimental arm. Our study team will meet with providers in the experimental arm to provide guidance on optimal antimicrobial-prescribing. We will provide personalized feedback to providers in the experimental arm once every quarter.
Also known as: Academic detailing
Percentage of Patient-visits Prescribed an Antimicrobial at Their ED Visit
This outcomes is defined as the total number of antimicrobial-prescribing visits divided by the total number of patient-visits. This metric will be calculated on a monthly basis for each site (2 intervention, 2 control). It will be calculated during the baseline and intervention periods. Therefore, each site will contribute 24 data points.
Time frame: This outcome will be calculated every month during the baseline and intervention periods. An interrupted time-series analysis will be performed to evaluate how this monthly percentage changed after the intervention period began.
Percentage of Patient-visits Prescribed a Late Antimicrobial Prescription More Than 24 Hours After But Within 30 Days of Their ED Visit
Late antimicrobial prescription is defined as the prescription of an (additional) antimicrobial by any provider more than 24 hours after but within 30 days of the patient's ED visit.
Time frame: For both intervention and control sites, the outcome will be reported as a monthly median, which is calculated across the 12 baseline and the 12 intervention months.
Percentage of Patient-visits Who Were Hospitalized More Than 24 Hours After But Within 30 Days of Their ED Visit
Hospitalization is defined as the need for hospitalization for any indication at a VA-facility more than 24 hours after but within 30 days of the patient's index visit to the ED.
Time frame: For both intervention and control sites, the outcome will be reported as a monthly median, which is calculated across the 12 baseline and the 12 intervention months.
Percentage of Patient-visits Who Died More Than 24 Hours After But Within 30 Days of Their ED Visit
Death is defined as all-cause death more than 24 hours after and within 30-days of the patient's ED visit.
Time frame: For both intervention and control sites, the outcome will be reported as a monthly median, which is calculated across the 12 baseline and the 12 intervention months.
Percentage of Patient-visits Who Underwent Clostridium Difficile Testing More Than 24 Hours After But Within 30 Days of Their ED Visit
Clostridium difficile testing is defined as a laboratory test for Clostridium difficile ordered more than 24 hours after but within 30-days of the patient's ED visit.
Time frame: For both intervention and control sites, the outcome will be reported as a monthly median, which is calculated across the 12 baseline and the 12 intervention months.
Percentage of Patient-visits Who Received Guideline Concordant Antimicrobial Management
This outcome was assessed using blinded manual chart reviews in a randomly selected sample of patients that met inclusion criteria, as outlined in our study protocol. For this reason, the denominators for this outcome will not match the patient counts for the other outcomes. If a patient received an antimicrobial when indicated or did not receive an antimicrobial when not indicated, the patient was deemed to have received guideline-concordant management. During the baseline period, 497 charts were randomly selected for review, and 480 ultimately underwent adjudication. During the intervention period, 576 charts were randomly selected for review, and 455 underwent adjudication.
Time frame: For the baseline and intervention periods, this outcome will be reported as the percentage of patients who received guideline-concordant management among the sample of qualifying ED visits that were randomly selected for manual chart review.
Percentage of Patient-visits Prescribed an Antibiotic at Their ED Visit
This outcomes is defined as the total number of antibacterial-prescribing visits divided by the total number of patient-visits. This metric will be calculated on a monthly basis for each site (2 intervention, 2 control). It will be calculated during the baseline and intervention periods. Therefore, each site will contribute 24 data points.
Time frame: This outcome will be calculated every month during the baseline and intervention periods. An interrupted time-series analysis will be performed to evaluate how this monthly percentage changed after the intervention period began.
We performed a quasi-experimental study with an interrupted time-series design and a matched-pair non-equivalent control group. There were 2 intervention sites and 2 control sites; 27/31 providers were enrolled at intervention sites. We measured outcomes in the PATIENTS seen at these 4 EDs. In a difference-in-differences analysis, outcomes were compared across intervention and control sites in patients seen before the intervention period (i.e. baseline) to those during the intervention period.
| Milestone | Audit-and-feedback | Control |
|---|---|---|
| Started | 2 | 2 |
| Completed | 2 | 2 |
| Not completed | 0 | 0 |
This outcomes is defined as the total number of antimicrobial-prescribing visits divided by the total number of patient-visits. This metric will be calculated on a monthly basis for each site (2 intervention, 2 control). It will be calculated during the baseline and intervention periods. Therefore, each site will contribute 24 data points.
| percentage of visits prescribed an abx | Patients Seen in the ED at Audit-and-feedback Sites | Patients Seen in the ED at Control Sites |
|---|---|---|
| Baseline | 21.2 | 20.9 |
| Intervention period | 19.1 | 21.6 |
Late antimicrobial prescription is defined as the prescription of an (additional) antimicrobial by any provider more than 24 hours after but within 30 days of the patient's ED visit.
| percentage of visits exposed to late abx | Patients Seen in the ED at Audit-and-feedback Sites | Patients Seen in the ED at Control Sites |
|---|---|---|
| Baseline | 31.5 (28.6 to 36.1) | 29.5 (26.5 to 31.9) |
| Intervention | 31.1 (28.6 to 35.8) | 28.5 (25.4 to 32.5) |
Hospitalization is defined as the need for hospitalization for any indication at a VA-facility more than 24 hours after but within 30 days of the patient's index visit to the ED.
| percentage of visits hospitalized | Patients Seen in the ED at Audit-and-feedback Sites | Patients Seen in the ED at Control Sites |
|---|---|---|
| Baseline | 5.9 (4.9 to 6.5) | 5.6 (4.9 to 6.1) |
| Intervention period | 5.9 (5.1 to 6.6) | 5.8 (5.2 to 6.3) |
Death is defined as all-cause death more than 24 hours after and within 30-days of the patient's ED visit.
| percentage of patient-visits who died | Patients Seen in the ED at Audit-and-feedback Sites | Patients Seen in the ED at Control Sites |
|---|---|---|
| Baseline | 0.56 (0.4 to 0.7) | 0.61 (0.4 to 0.8) |
| Intervention period | 0.60 (0.4 to 0.7) | 0.59 (0.5 to 0.8) |
Clostridium difficile testing is defined as a laboratory test for Clostridium difficile ordered more than 24 hours after but within 30-days of the patient's ED visit.
| percentage of visits tested | Patients Seen in the ED at Audit-and-feedback Sites | Patients Seen in the ED at Control Sites |
|---|---|---|
| Baseline | 0.60 (0.5 to 1.2) | 0.86 (0.7 to 1.2) |
| Intervention period | 0.69 (0.5 to 0.7) | 0.89 (0.7 to 1.2) |
This outcome was assessed using blinded manual chart reviews in a randomly selected sample of patients that met inclusion criteria, as outlined in our study protocol. For this reason, the denominators for this outcome will not match the patient counts for the other outcomes. If a patient received an antimicrobial when indicated or did not receive an antimicrobial when not indicated, the patient was deemed to have received guideline-concordant management. During the baseline period, 497 charts were randomly selected for review, and 480 ultimately underwent adjudication. During the intervention period, 576 charts were randomly selected for review, and 455 underwent adjudication.
| Participants | Patients Seen in the ED at Audit-and-feedback Sites | Patients Seen in the ED at Control Sites |
|---|---|---|
| Baseline | 125 | 123 |
| Intervention | 166 | 131 |
This outcomes is defined as the total number of antibacterial-prescribing visits divided by the total number of patient-visits. This metric will be calculated on a monthly basis for each site (2 intervention, 2 control). It will be calculated during the baseline and intervention periods. Therefore, each site will contribute 24 data points.
| % of visits prescribed an antibiotic | Patients Seen in the ED at Audit-and-feedback Sites | Patients Seen in the ED at Control Sites |
|---|---|---|
| Baseline | 20.8 (19.6 to 21.8) | 20.6 (18.7 to 22.2) |
| Intervention | 18.2 (16.8 to 19.6) | 20.6 (19.4 to 21.9) |
Collected over Outcomes were tracked for 30 days after each ED patient visit.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Patients Seen at Audit-and-feedback ED Sites During Intervention Period | 141/23,164 (0.6%) | 1,593/23,164 (6.9%) | 11/23,164 (0%) |
| Patients Seen at Control ED Sites During the Intervention Period | 176/28,835 (0.6%) | 1,863/28,835 (6.5%) | 27/28,835 (0.1%) |
| Patients Seen at Audit-and-feedback ED Sites During the Baseline Period | 146/28,016 (0.5%) | 1,810/28,016 (6.5%) | 193/28,016 (0.7%) |
| Patients Seen at Control EDs During the Baseline Period | 197/33,077 (0.6%) | 2,031/33,077 (6.1%) | 321/33,077 (1%) |
| Event | Patients Seen at Audit-and-feedback ED Sites During Intervention Period | Patients Seen at Control ED Sites During the Intervention Period | Patients Seen at Audit-and-feedback ED Sites During the Baseline Period | Patients Seen at Control EDs During the Baseline Period |
|---|---|---|---|---|
| Hospitalization >24 hours after but within 30 days of ED visitGeneral disorders | 1452/23164 | 1687/28835 | 1664/28016 | 1834/33077 |
| Mortality > 24 hours after ED visit and within 30 days of visitGeneral disorders | 141/23164 | 176/28835 | 146/28016 | 197/33077 |
| Event | Patients Seen at Audit-and-feedback ED Sites During Intervention Period | Patients Seen at Control ED Sites During the Intervention Period | Patients Seen at Audit-and-feedback ED Sites During the Baseline Period | Patients Seen at Control EDs During the Baseline Period |
|---|---|---|---|---|
| Clostridioides difficile infectionGastrointestinal disorders | 11/23164 | 27/28835 | 193/28016 | 321/33077 |
These numbers reflect patients seen in the 4 participating EDs during the baseline and intervention periods.
| Age, Continuous(years) | Patients Seen in the ED at Audit-and-feedback Sites During the Intervention Period | Patients Seen in the ED at Control Sites During the Intervention Period | Patients Seen in the ED at Audit-and-feedback Sites During the Baseline Period | Patients Seen in the ED at Control Sites During the Baseline Period | Total |
|---|---|---|---|---|---|
| Median | 60 (59 to 62) | 60 (59 to 61) | 60 (58 to 62) | 60 (59 to 60) | 60 (59 to 61) |
| Sex: Female, Male(Participants) | Patients Seen in the ED at Audit-and-feedback Sites During the Intervention Period | Patients Seen in the ED at Control Sites During the Intervention Period | Patients Seen in the ED at Audit-and-feedback Sites During the Baseline Period | Patients Seen in the ED at Control Sites During the Baseline Period | Total |
|---|---|---|---|---|---|
| Female | 2532 | 2627 | 3014 | 3159 | 11332 |
| Male | 20,632 | 26208 | 25002 | 29918 | 101760 |
| Race (NIH/OMB)(Participants) | Patients Seen in the ED at Audit-and-feedback Sites During the Intervention Period | Patients Seen in the ED at Control Sites During the Intervention Period | Patients Seen in the ED at Audit-and-feedback Sites During the Baseline Period | Patients Seen in the ED at Control Sites During the Baseline Period | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 204 | 336 | 243 | 361 | 1144 |
| Asian | 39 | 190 | 70 | 218 | 517 |
| Native Hawaiian or Other Pacific Islander | 55 | 125 | 94 | 158 | 432 |
| Black or African American | 5106 | 2720 | 5990 | 3215 | 17031 |
| White | 16343 | 23832 | 19893 | 27323 | 87391 |
| More than one race | 321 | 403 | 389 | 467 | 1580 |
| Unknown or Not Reported | 1096 | 1229 | 1337 | 1335 | 4997 |
| % of total visits prescribed an antimicrobial (monthly median)(Percentage of visits prescribed an abx) | Patients Seen in the ED at Audit-and-feedback Sites During the Intervention Period | Patients Seen in the ED at Control Sites During the Intervention Period | Patients Seen in the ED at Audit-and-feedback Sites During the Baseline Period | Patients Seen in the ED at Control Sites During the Baseline Period | Total |
|---|---|---|---|---|---|
| Median | 19.1 (17.8 to 20.4) | 21.6 (19.9 to 22.4) | 21.2 (20.3 to 23.7) | 20.9 (19.4 to 23.4) | 20.7 (19.4 to 22.5) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2018 to primary completion in Sep 2019, 11 months.
Results were first posted in Apr 2021, 1 year 6 months after primary completion.
Of 119 non-industry interventional studies with no phase under Respiratory Tract Infections, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's 11 months is below that.
Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Tract Infections →
Iowa City Veterans Affairs Medical Center